Gain Therapeutics Inc (GANX)
2.50
-0.01
(-0.40%)
USD |
NASDAQ |
May 10, 16:00
2.50
0.00 (0.00%)
After-Hours: 19:30
Gain Therapeutics Debt to Equity Ratio
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| March 31, 2023 | 0.0388 |
| December 31, 2022 | 0.032 |
| September 30, 2022 | 0.0258 |
| June 30, 2022 | 0.0232 |
| March 31, 2022 | 0.0203 |
| Date | Value |
|---|---|
| December 31, 2021 | 0.0199 |
| September 30, 2021 | 0.0188 |
| June 30, 2021 | 0.0172 |
| March 31, 2021 | 0.0163 |
| December 31, 2020 | 0.119 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
0.0163
Minimum
Mar 2021
0.119
Maximum
Dec 2020
0.0331
Average
0.0217
Median
Debt to Equity Ratio Benchmarks
| Eli Lilly and Co | 2.046 |
| Alpine Immune Sciences Inc | 0.00 |
| Outlook Therapeutics Inc | -- |
| OptiNose Inc | -1.504 |
| Greenwich LifeSciences Inc | -- |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 18.61M |
| Total Liabilities (Quarterly) | 6.031M |
| Shareholders Equity (Quarterly) | 12.58M |